Anika Therapeutics Inc (ANIK) valuation
Anika Therapeutics P/E ratio history
Anika Therapeutics has no meaningful price to earnings ratio at the last close, which happens when earnings over the last twelve months are negative or close to zero. At its last 5 fiscal year ends its P/E ranged from 22.8 (year to Dec 2016) to 128.0 (year to Dec 2021), with a median of 26.1.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $9.61 | -$0.76 | n/m |
| Dec 31, 2024 | $16.46 | -$3.83 | n/m |
| Dec 31, 2023 | $22.66 | -$5.64 | n/m |
| Dec 31, 2022 | $29.60 | -$1.02 | n/m |
| Dec 31, 2021 | $35.83 | $0.28 | 128.0 |
| Dec 31, 2020 | $45.26 | -$1.69 | n/m |
| Dec 31, 2019 | $51.85 | $1.92 | 27.0 |
| Dec 31, 2018 | $33.61 | $1.29 | 26.1 |
| Dec 31, 2017 | $53.91 | $2.12 | 25.4 |
| Dec 31, 2016 | $48.96 | $2.15 | 22.8 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Anika Therapeutics valuation against its peers
| Company | Market value | Forward P/E | Price / sales |
|---|---|---|---|
| Anika TherapeuticsANIK | $279M | 21.0 | 2.3 |
| Treace Medical ConceptsTMCI | $287M | — | 1.4 |
| Orasure TechnologiesOSUR | $271M | — | 2.4 |
| Rocket PharmaceuticalsRCKT | $266M | — | — |
| Bioage LabsBIOA | $261M | — | 25.2 |
| Editas MedicineEDIT | $261M | — | 5.6 |
| Benitec BiopharmaBNTC | $300M | — | — |
| Sanara MedtechSMTI | $301M | 88.8 | 2.7 |
| Larimar TherapeuticsLRMR | $257M | — | — |
| Peer median | 88.8 | 2.7 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ANIK financials · ANIK returns
No forecast, no recommendation. This page describes Anika Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.